Details

Autor(en) / Beteiligte

• Lin, Richard J
• Artz, Andrew S

Titel

Allogeneic hematopoietic cell transplantation for older patients

Ist Teil von

• Hematology, 2021-12, Vol.2021 (1), p.254-263

Ort / Verlag

United States: American Society of Hematology

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• Hematologic malignances are more common and often higher risk in older patients. Allogeneic hematopoietic cell transplantation (alloHCT) best enables long-term disease control for patients with poor risk or relapsed/refractory hematologic malignancies such as acute myeloid leukemia, myelodysplastic syndromes, or myelofibrosis. Rates of alloHCT among older patients, while still relatively low compared with younger patients, have risen sharply over the past decade. Accumulating evidence supports alloHCT for patients ≥60 years of age relative to non-HCT therapies based on improved overall and disease-free survival. However, a significant proportion of older adults have limitations characterized by geriatric assessment. A systematic process to evaluate and optimize older patients may improve decision making, transplant outcomes, and alloHCT access. We present case-based studies to illustrate a stepwise and rational approach to proper older patient evaluation, pretransplant optimization, and posttransplant care with attention to important geriatric issues and quality of life.